PAREXEL Launches ClinPhone RTSM Mobile App to Improve Supply Management and Increase Patient Safety
February 13 2017 - 8:00AM
Business Wire
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, today launched a mobile
app for the ClinPhone® RTSM (randomization and trial supply
management) service. The app is designed to enhance clinical trial
supply management processes, increase patient safety, and improve
the chain of custody record for clinical supplies.
Using built-in barcode scanning capabilities, clinical trial
site staff, including principal investigators (PIs), study nurses,
and clinical research associates (CRAs), can utilize the app to
streamline common clinical trial responsibilities. Tasks including
confirming correct treatment allocation, dispensing to patients,
and processing of medicinal product returns can now be managed more
efficiently, reducing time and human errors.
“Clinical trials management is often hampered by administrative
supply-related tasks at site locations. Simplifying systems and
processes and removing manual data entry can save staff time and
increase patient safety,” said Ken Faulkner, Corporate Vice
President, PAREXEL Informatics. “Our mobile app is the latest
extension of the ClinPhone RTSM service, further demonstrating our
commitment to simplifying the drug development journey through the
innovative application of social, mobile, analytic, and cloud
technologies.”
PAREXEL’s ClinPhone RTSM service has been deployed on over 3,700
studies and more than 2.5 million patients, with the largest of
those studies randomizing and supplying more than 60,000 patients.
The ClinPhone RTSM mobile app is available worldwide for use on
Android and iOS platforms. For more details, please visit:
https://www.parexel.com/solutions/informatics/randomization-and-trial-supply-management/rtsm-mobile-app.
About PAREXEL InternationalPAREXEL International
Corporation is a leading global biopharmaceutical services company,
providing a broad range of expertise-based clinical research,
consulting, medical communications, and technology solutions and
services to the worldwide pharmaceutical, biotechnology and medical
device industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, and
reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the clinical
development process. Headquartered near Boston, Massachusetts,
PAREXEL has offices in 85 locations in 51 countries around the
world, and had approximately 19,625 employees in the first quarter.
For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170213005088/en/
Media:Dana RobieTel.: +1 781-434-4772Email:
Dana.Robie@PAREXEL.comorJenny Radloff, PAN CommunicationsTel: +1
617-502-4300Email: PAREXEL@pancomm.comorInvestors:Ronald
AldridgeTel.: +1-781-434-4753Email: ron.aldridge@PAREXEL.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2024 to May 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From May 2023 to May 2024